Gastroenterology
Gastroenterology is a sub-specialty of internal medicine that deals with the study and management of disorders related to the digestive system or the gastrointestinal (GI) tract. It focuses on assessing and treating medical disorders related to organs such as the oesophagus, stomach, small intestine, colon & rectum, pancreas, gallbladder, bile ducts, and liver.
Heartburn is a common symptom of Gastroesophageal reflux disease, a widespread gastrointestinal disorder. NAFLD, NASH, IBD, IBS, pancreatitis come in main domain area of gastroenterologist.
Gastroenterology Medicine Manufacturer
Aprazer Healthcare Redefines Gastroenterology care by developing premium-quality therapeutics, including both over-the-counter and prescription medicines.
Aprazer Healthcare Develops Cost-effective Treatments
Recognizing the demand for cost-effective treatments in IBD and MASH.
We develop scientifically backed solutions for organic GI disorders, addressing the critical patient needs – bridging the gap of unavailability, inadequate therapeutic efficacy, and affordability.
Reliable Effective Care
With our strong foundation and expertise in gastroenterology, we prioritize reliability, creating solutions that are both safe and effective.
Expanding the Frontiers of Gastroenterology & Hepatology
From developing the first-line treatment for Primary Biliary Cholangitis (PBC), Udikast (UDCA) 300 mg, and the Ocabest 5 mg, (OCA) with stronger ant fibrotic effects, we develop the widest range of gastroenterology and hepatology treatments including:
- 1. Proton pump inhibitors
- 2. Anti-inflammatory Agents
- 3. Gastrointestinal-selective antibiotics
- 4. Hepatoprotective Agents
Leaders in Gastroenterology Medicine Manufacturers, Suppliers, and Exporters
- • With a high degree of supply assurance
- • Manufacture capacity of 100 multi-tones
- • Suppliers to more than 20 countries
We are well-positioned to meet the global demand for gastroenterology and hepatology therapeutics.
Shaping the Future in Digestive Care
We focus on advancing breakthrough therapeutics to reduce the global burden of gastrointestinal disorders, Such as IBD, NAFLD, NASH, Gastritis, and ulcerative colitis.
Our premium-selling medications—EPRAKAST DSR, targeting acid-related gastric disorders, and RIFAXIGEM-500, for bacterial-induced GIT infections—have been the top gastroenterologists’ choice.
